High-sensitivity C-reactive protein in paediatric inflammatory bowel disease

World Journal of Gastroenterology

Volumn 16, Issue 23, 2010, Pages 2901-2906

  Sidoroff, Marianne ^a   Karikoski, Riitta ^b   Raivio, Taneli ^a   Savilahti, Erkki ^a   Kolho, Kaija Leena ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

C reactive protein; Children; Crohn's disease; Inflammatory markers; Ulcer ative colitis

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; BUDESONIDE; C REACTIVE PROTEIN; GLUCOCORTICOID; INFLIXIMAB; MESALAZINE; PREDNISOLONE; STEROID; BIOLOGICAL MARKER;

ACNE; ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLONOSCOPY; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; FEMALE; HISTOPATHOLOGY; HUMAN; ILEOCECAL VALVE; ILEUM; INFANT; MALE; MOON FACE; PEDIATRICS; PRESCHOOL CHILD; PROTEIN BLOOD LEVEL; SCHOOL CHILD; SENSITIVITY ANALYSIS; SIDE EFFECT; STRIA; SYSTEMIC THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; ULCERATIVE COLITIS; BLOOD; CASE CONTROL STUDY; INFLAMMATORY BOWEL DISEASES; LIMIT OF DETECTION;

ADOLESCENT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COLITIS, ULCERATIVE; CROHN DISEASE; FEMALE; GLUCOCORTICOIDS; HUMANS; INFANT; INFLAMMATORY BOWEL DISEASES; LIMIT OF DETECTION; MALE;

EID: 77954268512     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v16.i23.2901     Document Type: Article

References (30)

1. Marnell L, Mold C, Du Clos TW. C-reactive protein: ligands, receptors and role in inflammation. Clin Immunol 2005; 117: 104-111
2. Vermeire S, Van Assche G, Rutgeerts P. C-reactive protein as a marker for inflammatory bowel disease. Inflamm Bowel Dis 2004; 10: 661-665
3. Ford ES, Giles WH, Myers GL, Rifai N, Ridker PM, Mannino DM. C-reactive protein concentration distribution among US children and young adults: findings from the National Health and Nutrition Examination Survey, 1999-2000. Clin Chem 2003; 49: 1353-1357
4. Black S, Kushner I, Samols D. C-reactive Protein. J Biol Chem 2004; 279: 48487-48490
5. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11: 707-712
6. Henriksen M, Jahnsen J, Lygren I, Stray N, Sauar J, Vatn MH, Moum B. C-reactive protein: a predictive factor and marker of inflammation in inflammatory bowel disease. Results from a prospective population-based study. Gut 2008; 57: 1518-1523
7. Fagan EA, Dyck RF, Maton PN, Hodgson HJ, Chadwick VS, Petrie A, Pepys MB. Serum levels of C-reactive protein in Crohn's disease and ulcerative colitis. Eur J Clin Invest 1982; 12: 351-359
8. Schreiber S, Rutgeerts P, Fedorak RN, Khaliq-Kareemi M, Kamm MA, Boivin M, Bernstein CN, Staun M, Thomsen OØ, Innes A. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-818
9. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, Panaccione R, Sanders M, Schreiber S, Targan S, van Deventer S, Goldblum R, Despain D, Hogge GS, Rutgeerts P. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353: 1912-1925
10. Beattie RM, Walker-Smith JA, Murch SH. Indications for investigation of chronic gastrointestinal symptoms. Arch Dis Child 1995; 73: 354-355
11. Zilberman L, Maharshak N, Arbel Y, Rogowski O, Rozenblat M, Shapira I, Berliner S, Arber N, Dotan I. Correlated expression of high-sensitivity C-reactive protein in relation to disease activity in inflammatory bowel disease: lack of differences between Crohn's disease and ulcerative colitis. Digestion 2006; 73: 205-209
12. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol Suppl 1989; 170: 2-6; discussion 16-19
13. Vihinen MK, Raivio T, Verkasalo M, Jänne OA, Kolho KL. Circulating glucocorticoid bioactivity during peroral glucocorticoid treatment in children and adolescents with inflammatory bowel disease. J Clin Gastroenterol 2008; 42: 1017-1024
14. Turner D, Otley AR, Mack D, Hyams J, de Bruijne J, Uusoue K, Walters TD, Zachos M, Mamula P, Beaton DE, Steinhart AH, Griffiths AM. Development, validation, and evaluation of a pediatric ulcerative colitis activity index: a prospective multicenter study. Gastroenterology 2007; 133: 423-432
15. Vihinen MK, Kolho KL, Jänne OA, Andersson S, Raivio T. Circulating adiponectin as a marker for glucocorticoid-related side effects in children and adolescents with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2009; 48: 504-506
16. Vihinen MK, Kolho KL, Ashorn M, Verkasalo M, Raivio T. Bone turnover and metabolism in paediatric patients with inflammatory bowel disease treated with systemic glucocorticoids. Eur J Endocrinol 2008; 159: 693-698
17. D'Haens GR, Geboes K, Peeters M, Baert F, Penninckx F, Rutgeerts P. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114: 262-267
18. Sipponen T, Kärkkäinen P, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Färkkilä M. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn's disease and histological findings. Aliment Pharmacol Ther 2008; 28: 1221-1229
19. Kolho KL, Raivio T, Lindahl H, Savilahti E. Fecal calprotectin remains high during glucocorticoid therapy in children with inflammatory bowel disease. Scand J Gastroenterol 2006; 41: 720-725
20. Florin TH, Paterson EW, Fowler EV, Radford-Smith GL. Clinically active Crohn's disease in the presence of a low C-reactive protein. Scand J Gastroenterol 2006; 41: 306-311
21. Desreumaux P, Ernst O, Geboes K, Gambiez L, Berrebi D, Müller-Alouf H, Hafraoui S, Emilie D, Ectors N, Peuchmaur M, Cortot A, Capron M, Auwerx J, Colombel JF. Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. Gastroenterology 1999; 117: 73-81
22. Colombel JF, Solem CA, Sandborn WJ, Booya F, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Bodily KD, Fletcher JG. Quantitative measurement and visual assessment of ileal Crohn's disease activity by computed tomography enterography: correlation with endoscopic severity and C reactive protein. Gut 2006; 55: 1561-1567
23. Peyrin-Biroulet L, Chamaillard M, Gonzalez F, Beclin E, Decourcelle C, Antunes L, Gay J, Neut C, Colombel JF, Desreumaux P. Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? Gut 2007; 56: 577-583
24. Heresbach D, Alexandre JL, Branger B, Bretagne JF, Cruchant E, Dabadie A, Dartois-Hoguin M, Girardot PM, Jouanolle H, Kerneis J, Le Verger JC, Louvain V, Politis J, Richecoeur M, Robaszkiewicz M, Seyrig JA. Frequency and significance of granulomas in a cohort of incident cases of Crohn's disease. Gut 2005; 54: 215-222
25. Rubio CA, Orrego A, Nesi G, Finkel Y. Frequency of epithelioid granulomas in colonoscopic biopsy specimens from paediatric and adult patients with Crohn's colitis. J Clin Pathol 2007; 60: 1268-1272
26. De Matos V, Russo PA, Cohen AB, Mamula P, Baldassano RN, Piccoli DA. Frequency and clinical correlations of granulomas in children with Crohn disease. J Pediatr Gastroenterol Nutr 2008; 46: 392-398
27. Glasser AL, Boudeau J, Barnich N, Perruchot MH, Colombel JF, Darfeuille-Michaud A. Adherent invasive Escherichia coli strains from patients with Crohn's disease survive and replicate within macrophages without inducing host cell death. Infect Immun 2001; 69: 5529-5537
28. Poullis AP, Zar S, Sundaram KK, Moodie SJ, Risley P, Theodossi A, Mendall MA. A new, highly sensitive assay for C-reactive protein can aid the differentiation of inflammatory bowel disorders from constipation- and diarrhoeapredominant functional bowel disorders. Eur J Gastroenterol Hepatol 2002; 14: 409-412
29. Maharshak N, Arbel Y, Gal-Oz A, Rogowski O, Shapira I, Berliner S, Vered Y, Canaani J, Dotan I. Comparative analysis of Bayer wide-range C-reactive protein (wr-CRP) and the Dade-Behring high sensitivity C-reactive protein (hs-CRP) in patients with inflammatory bowel disease. J Dig Dis 2008; 9: 140-143
30. Kushner I, Rzewnicki D, Samols D. What does minor elevation of C-reactive protein signify? Am J Med 2006; 119: 166. e17-166.e28